LEXINGTON, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Company management will participate in the following upcoming investor conferences:
- Guggenheim Healthcare Talks Rare Disease and Genomic Medicines Day: The Company will host one-on-one meetings at the Guggenheim Healthcare Talks Rare Disease and Genomic Medicines Day on Tuesday, April 2, 2019 at Le Meridien in Cambridge, MA.
- 18th Annual Needham Healthcare Conference: The Company will host one-on-one meetings and give a corporate presentation at 1:30 p.m. Eastern Time at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at the Westin New York Grand Central in New York, NY. A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcast will be archived for 30 days following the presentation.
About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The Company’s MRT platform is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. Translate Bio believes that its MRT platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system and lymphatic system. The Company also believes its MRT platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. Translate Bio’s two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.
Source: Translate Bio, Inc.